Special Issue "Thrombosis and Coagulopathy"

A special issue of Diseases (ISSN 2079-9721). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (16 April 2021).

Special Issue Editor

Dr. Antonio Chistolini
E-Mail Website
Guest Editor
Hematology Department of Translational and Precision Medicine, Sapienza University of Rome, Italy.
Interests: thrombosis; hematological malignancy; coagulopathy.

Special Issue Information

Dear Colleagues,

Cancer patients are at higher risk of developing thromboembolic events. Low-molecular-weight heparin remains the standard anticoagulant therapy in a cancer setting. However, direct oral anticoagulants have recently changed the therapeutic approach to the treatment of venous thromboembolism in cancer patients.

This Special Issue will focus on the treatment of venous thromboembolism in patients affected by solid and hematologic malignancies.

Dr. Antonio Chistolini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • venous thromboembolism
  • anticoagulant therapy
  • thromboembolic risk
  • cancer-related thrombosis
  • congenital coagulopathy
  • acquired coagulopathy.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Cancer-Associated Thrombosis: A New Light on an Old Story
Diseases 2021, 9(2), 34; https://doi.org/10.3390/diseases9020034 - 04 May 2021
Viewed by 186
Abstract
Cancer-associated thrombosis (CAT) is a rising and significant phenomenon, becoming the second leading cause of death in cancer patients. Pathophysiology of CAT differs from thrombosis in the non-cancer population. There are additional risk factors for thrombosis specific to cancer including cancer type, histology, [...] Read more.
Cancer-associated thrombosis (CAT) is a rising and significant phenomenon, becoming the second leading cause of death in cancer patients. Pathophysiology of CAT differs from thrombosis in the non-cancer population. There are additional risk factors for thrombosis specific to cancer including cancer type, histology, and treatment, such as chemotherapy. Recently developed scoring systems use these risk factors to stratify the degree of risk and encourage thromboprophylaxis in intermediate- to high-risk patients. Anticoagulation is safely used for prophylaxis and treatment of CAT. Both of these have largely been with low-molecular-weight heparin (LMWH), rather than the vitamin K antagonist (VKA); however, there has been increasing evidence for direct oral anticoagulant (DOAC) use. Consequently, international guidelines have also adapted to recommend the role of DOACs in CAT. Using DOACs is a turning point for CAT, but further research is warranted for their long-term risk profile. This review will discuss mechanisms, risk factors, prophylaxis and management of CAT, including both LMWH and DOACs. There will also be a comparison of current international guidelines and how they reflect the growing evidence base. Full article
(This article belongs to the Special Issue Thrombosis and Coagulopathy)
Show Figures

Figure 1

Back to TopTop